New immunotherapy tested for Tough-to-Treat lung cancers
NCT ID NCT07016230
Summary
This study is testing an experimental immunotherapy drug called tarlatamab in people with advanced small-cell lung cancer or similar neuroendocrine cancers that have worsened after standard treatment. About 40 participants will receive the drug through an IV to see if it can shrink tumors and control the disease. Researchers will also collect blood and tissue samples to understand how the drug works and why some cancers might resist it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.